The government has brought 137 non-scheduled anti-cancer drugs under Trade Margin Rationalization, potentially reducing their ...

A case report found enlarging pulmonary cavities despite regressing solid components and thinning walls, complicating ...

Colorectal Cancer Trials to Watch at ESMO 2026 / cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical trials, colorectal cancer, ...

The issue of education and treatment of breast cancer is back in the spotlight, especially during Breast Cancer Awareness ...

A retrospective single-center cohort of 128 patients associated frontline bevacizumab with longer overall survival in ...

KRAS G12D, INCA33890 and CDK2 combos show solid tumor promise ahead of Jakafi LOE—click for more on INCY stock.

In the ALK-rearranged NCI-H3122 model, ATNM-400 plus crizotinib achieved 97% TGI, compared with 50% for ATNM-400, 55% for crizotinib and 26% for patritumab deruxtecan alone. ATNM-400-containing ...

The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...

Flatiron Health today announced that four research abstracts will be presented as e-posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, ...

Actinium Pharmaceuticals (NYSE American: ATNM) presented preclinical results for its investigational drug ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), ...

Actinium Pharmaceuticals, Inc. announced new preclinical results demonstrating the broad antitumor potential of ATNM-400 across non-small cell lung cancer (NSCLC), colorectal cancer and ovarian cancer ...